ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 26 • 2014 ACR/ARHP Annual Meeting

    Functional Osteoclasts Differentiate Spontaneously from the Rheumatoid Joint

    Stinne Greisen1, Halldór Bjarki Einarsson2, Malene Hvid3, Ellen Margrethe Hauge4,5, Bent Deleuran3,6 and Tue Kragstrup7, 1Dept of Biomedicine, Aarhus University, Aarhus, Denmark, 2Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, 3Department of Biomedicine, Aarhus University, Aarhus, Denmark, 4Dept. of Anatomi, Aarhus University, Aarhus, Denmark, 5Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 7Aarhus University, Aarhus, Denmark

    Functional osteoclasts differentiate spontaneously from the rheumatoid joint Background/Purpose Osteoimmunology is a field of emerging interest in which bone formation and resorption are understood in…
  • Abstract Number: 25 • 2014 ACR/ARHP Annual Meeting

    DC-STAMP Modulates Osteoblast Differentiation and Regulates Bone Repair

    Yahui Grace Chiu1, Tzong-Ren Sheu2, Jinbo Li3, Dongge Li1, Michael Thullen2, Brendan Boyce4, Edward Puzas2 and Christopher T. Ritchlin5, 1Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Pathology, University of Rochester, Rochester, NY, 4Pathology, University of Rochester, Rocehster, NY, 5Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose Patients with osteoporosis and the elderly have an increased risk of bone fracture. Currently, no biomarker is available to assess bone healing status in…
  • Abstract Number: 24 • 2014 ACR/ARHP Annual Meeting

    Netrin1 Is Highly Expressed and Required in Inflammatory Infiltrates in Wear Particle-Induced Osteolysis

    Aranzazu Mediero1, Bhama Ramkhelawon2, Ed Purdue3, Steven R. Goldring4, Kathryn Moore2 and Bruce N. Cronstein5, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, 3535 East 70th Street, Hospital for Special Surgery, New York, NY, 4Hospital for Special Surgery, New York, NY, 5NYU School of Medicine, Division of Rheumatology, New York, NY

    Background/Purpose Osteoclasts play a critical role in homeostatic bone turnover and pathologic bone destruction. Netrin-1, expressed in the marrow only by osteoclast precursors, acts in…
  • Abstract Number: 23 • 2014 ACR/ARHP Annual Meeting

    Activation of EPAC1/2 Is Essential for Osteoclast Formation By Modulating NFkB Nuclear Translocation and Actin Cytoskeleton Rearrangements

    Aranzazu Mediero1, Miguel Perez-Aso2 and Bruce N. Cronstein3, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2545 1st Ave., New York University, New York City, NY, 3NYU School of Medicine, Division of Rheumatology, New York, NY

    Background/Purpose Bisphosphonates inhibit osteoclast differentiation/function via inhibition of Rap1A isoprenylation and cytoskeletal assembly. As Rap1 is the effector of EPAC proteins (exchange protein directly activated…
  • Abstract Number: 1 • 2014 ACR/ARHP Annual Meeting

    Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome

    William Ruff1, Silvio M. Vieira2, Cassyanne Aguiar3,4, John Sterpka2, Andrew Goodman5, Doruk Erkan3,6 and Martin Kriegel1,7, 1Immunobiology, Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3New York Presbyterian/Weill Cornell Medical Center, New York, NY, 4Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, 5Microbial Pathogenesis, Yale School of Medicine, Microbial Diversity Institute, New Haven, CT, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune clotting disorder of unknown etiology targeting a major autoantigen, β2-glycoprotein I (β2GPI). Infectious triggers have been implicated in…
  • Abstract Number: L12 • 2014 ACR/ARHP Annual Meeting

    Immunological Phenotyping of a Cohort of American Travelers with Chikungunya Viral Arthritis

    Jonathan Miner1, Han Xian Aw yeang1, Julie Fox1, Samantha Taffner1, Alfred Kim2, Michael Diamond1, Deborah Lenschow3 and Wayne Yokoyama1,4, 1Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, 2Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, 3Washington University in Saint Louis School of Medicine, Saint Louis, MO, 4Howard Hughes Medical Institute, Saint Louis, MO

    Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that spread to the United States in 2014.  After an initial period of acute…
  • Abstract Number: L8 • 2014 ACR/ARHP Annual Meeting

    Differential DNA Methylation Associated with Lupus Nephritis

    Renuka Nayak1, Sharon A. Chung2, Joanne Nitiham3 and Lindsey A. Criswell3, 1Rheumatology, University of California - San Francisco, San Francisco, CA, 2School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 3Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA

    Background/Purpose: Genetic and epigenetic factors contribute to the progression of systemic lupus erythematosus (SLE).  We now have technologies that allow us to identify these factors…
  • Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting

    Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound

    Miroslav Harjacek1, Mandica Vidovic2, Lovro Lamot2,3, Marija Perica2 and Lana Tambic Bukovac2, 1Rheumatology, Children's Hospital Srebrnjak, Zagreb, Croatia, 2Children's Hospital Srebrnjak, Zagreb, Croatia, 3University of Zagreb School of Medicine, Zagreb, Croatia

    Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…
  • Abstract Number: L20 • 2014 ACR/ARHP Annual Meeting

    BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study

    Jonathan Kay1, Michael Wyand2, Srikantiah Chandrashekara3, Davy Jacob Olakkengil4, Kaushik Bhojani5, Girish Bhatia6, Gaurav Rathi7, Suresh Maroli8, Elizabeth Thomson9, Cheryl Lassen10, Lucy Shneyer11 and Arvind Chopra12, 1UMass Memorial Medical Center, Worcester, MA, 2Epirus Biopharmaceuticals, Boston, MA, 3Chanre Rheumatology and Immunology Centre and Research, Bangalore, India, 4St. John’s Medical College Hospital, Bengaluru, India, 5Department of Rheumatology, Fortis Hospital, Mumbai, India, 6Pentagon Multispeciality Clinic and Research Centre, Pune, India, 7Rathi Hospital, Ahmedabad, India, 8Reliance Life Sciences, Mumbai, India, 9Elizabeth Thomson LTD, London, MA, United Kingdom, 10Epirus Biopharmaceuticals, Zug, Switzerland, 11Shneyer Statistics LLC, Denville, NJ, 12Rheumatology, Center for Rheumatic Diseases, Pune, India

    Background/Purpose: Over the first 16 wks of this phase 3 double-blind (DB) comparative effectiveness clinical trial, the comparable proportion of ACR20 responders for BOW015 (a…
  • Abstract Number: 15 • 2014 ACR/ARHP Annual Meeting

    Performance of an Automated Chemiluminescence Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein I Antibodies Detection in a Cohort of 400 Clinically Characterized Consecutive Routine Samples

    Alessandra Zanola1, Laura Andreoli1, Cecilia Nalli1, Flavio Allegri1, Michael Mahler2, Gary Norman3 and Angela Tincani1, 1Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 2Research, INOVA Diagnostics, San Diego, CA, 3INOVA Diagnostics, San Diego, CA

    Background/Purpose: Several immunoassays are available for the detection of anti-cardiolipin (aCL) and anti-beta2glycoprotein I antibodies (anti-B2GPI), but standardization and harmonization of these tests is an…
  • Abstract Number: 14 • 2014 ACR/ARHP Annual Meeting

    Rivaroxaban Use in Patients with Antiphospholipid Syndrome Patients and Previous Poor Anticoagulation Control with Vitamin K Antagonists

    Savino Sciascia1 and Beverley Hunt2, 1Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2St Thomas Hospital, London, UK, Thrombosis and Thrombophilia Center (St Thomas Hospital, London, UK), London, United Kingdom

    Background/Purpose: Management of antiphospholipid syndrome (APS) centres on attenuating the procoagulant state whilst balancing the bleeding risks of anticoagulant therapy. In a minority of APS…
  • Abstract Number: 13 • 2014 ACR/ARHP Annual Meeting

    Eculizumab in Antiphospholipid Antibody Syndrome

    Ekaterini Zapantis1, Richard Furie2 and Diane Horowitz1, 1Rheumatology, North Shore - Long Island Jewish Health System, Great Neck, NY, 2Division of Rheumatology and Allergy-Clinical Immunology, North Shore - Long Island Jewish Health System, Great Neck, NY

    Background/Purpose Antiphospholipid syndrome (APS) is defined as the occurrence of venous or arterial thrombosis and/or pregnancy morbidity, in the presence of serological evidence of antiphospholipid…
  • Abstract Number: 12 • 2014 ACR/ARHP Annual Meeting

    Non-Criteria Antiphospholipid Antibodies in Obstetrical “seronegative Anti-Phospholipid syndrome”

    Arsene Mekinian1, Marie Charlotte Bourrienne2, Lionel Carbillon3, Sabine Grootenboer2, Luc Dechaisemartin4, Sylvie chollet Martin2, Olivier Fain5 and Pascale Nicaise-Roland6, 1Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France, 2Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, 3Service de gynécologie-obstétrique, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, 4Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, PARIS, France, 5Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, 6Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, Paris, France

    Background/Purpose The aims of our prospective study were to determine the prevalence of non-criteria aPL and their clinical relevance in a seronegative population with pregnancy…
  • Abstract Number: 10 • 2014 ACR/ARHP Annual Meeting

    Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients

    Mileka Gilbert1 and Lenore M. Buckley2, 1Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 2Section of Rheumatology, Yale School of Medicine, New Haven, CT

    Background/Purpose: An association between anti-phospholipid antibodies (aPL abs) and non-thrombotic neuropsychiatric events has been reported in pediatric and adult patients, including patients who do not…
  • Abstract Number: 9 • 2014 ACR/ARHP Annual Meeting

    A Risk-Stratified Perioperative Management Strategy for Antiphospholipid Antibody Positive Patients Undergoing Kidney Transplantation

    Vinicius Domingues1, Darshana Dadhania2, Choli Hartono2, Raymond Pastore3 and Doruk Erkan4, 11320 York Avenue 17n, New York Presbyterian Hospital, New York, NY, 2Nephrology and Hypertension, New York Presbyterian Hospital, new york, NY, 3Hematology and Oncology, New York Presbyterian Hospital, new york, NY, 4Rheumatology, Hospital for Special Surgery; Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY

    Background/Purpose: Antiphospholipid antibody (aPL) positive patients undergoing kidney transplantation (Tx) are at increased risk for perioperative complications. The objective of this study was to analyze…
  • « Previous Page
  • 1
  • …
  • 2230
  • 2231
  • 2232
  • 2233
  • 2234
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology